Combination Drug Pricing Rules Under Japan NHI

Fixed-dose combination (FDC) products present a distinct pricing challenge under Japan's National Health Insurance system. When two or more active ingredients are formulated together, the MHLW and Chuikyo must determine a price that reflects both the individual components' values and any incremental benefit — or convenience — that the combination delivers. Getting this calculation right is critical for any market access team launching or repositioning a combination product in Japan.

How Japan Prices Fixed-Dose Combinations

For FDC products that combine two already-listed NHI ingredients, the baseline pricing approach starts from the individual listed prices of those components. The standard calculation adds the component prices together and then applies adjustments based on whether the combination offers demonstrable clinical advantages over taking the two drugs separately.

If the combination is shown to improve patient outcomes — for instance, by enhancing bioavailability, reducing adverse events, or enabling synergistic pharmacodynamic effects — a combination usefulness premium may be applied. This premium is evaluated by Chuikyo using clinical data submitted in the pricing dossier.

Conversely, if the combination is viewed primarily as a convenience formulation (reducing pill burden without additional therapeutic value), a deduction is typically applied to the summed component price — usually in the range of 5–10% — reflecting the assumption that a convenience combination does not justify the full sum of separate components.

For novel FDC products where one or both active ingredients are being listed for the first time, the pricing follows standard new drug rules, with the innovation and usefulness premium framework applied to the combination as a whole.

Oncology and Immunotherapy Combinations

Combination regimens have become central to oncology and immunology, creating ongoing complexity in Japan's NHI pricing environment. Checkpoint inhibitors combined with chemotherapy, or two targeted agents used together, raise the question of whether the combination should be priced as a single entity or managed as co-listed individual drugs used in combination therapy.

Under Japan's framework, when two separately approved drugs are used together in a defined regimen — rather than formulated as a single product — each drug retains its individual listed price. The combined cost to the NHI is therefore the sum of both drugs' prices at the prescribed doses. Chuikyo reviews these combination regimens when they represent a significant new clinical standard, but the pricing lever is typically applied to the individual drugs rather than the combination as a unit.

This distinction matters for cost-effectiveness assessments. When cost-effectiveness analysis (CEA) is triggered — currently applicable to drugs with estimated annual NHI expenditure above defined thresholds — the CEA may evaluate the combination regimen as a clinical unit even though pricing is managed drug by drug.

The FY2026 Context: Spillover Rule Abolition

One development particularly relevant to combination product strategy is Japan's abolition of the Market Expansion Repricing (MER) spillover rule in the FY2026 revision. Previously, when a drug triggered MER (due to sales substantially exceeding the original NHI forecast), therapeutically similar drugs in the same category could be subject to price reductions through the spillover mechanism — even if those drugs had not themselves exceeded sales thresholds.

For combination products that share components with high-selling monotherapies, the old spillover rule created a risk of indirect price pressure. The elimination of this mechanism in April 2026 reduces that exposure and provides somewhat more pricing stability for FDC products whose individual ingredients are commercially successful.

Practical Considerations for Market Access Teams

When preparing a combination drug pricing submission for Japan, several principles guide best outcomes:

Quantify the clinical differentiation clearly. Chuikyo responds to evidence-backed claims of comparative benefit. Vague assertions of synergy are unlikely to secure a usefulness premium. Head-to-head clinical data comparing the FDC to co-administration of the separate components — where available — carries significant weight.
Understand how your comparator is priced. If the existing standard of care involves two separately prescribed drugs, your pricing dossier should clearly map the FDC's cost relationship to that standard. Demonstrating cost-neutral or cost-saving outcomes while improving adherence is a defensible position in Chuikyo review.
Track component price trajectories. Each NHI revision cycle may reprice one or both of a combination's underlying components, which can affect the combination product's relative value positioning in subsequent renewal discussions.
Monitor annual revision impacts. Japan shifted to annual price revisions beginning in 2021, meaning combination products face potential repricing every year rather than every two years. Staying current on listed price data across the NHI formulary is no longer optional for market access teams — it is an operational necessity.

NHI Price Wire tracks listed prices for over 17,000 drugs across Japan's NHI system, including fixed-dose combinations and the individual components they draw from. Monitor revision-cycle changes in real time — visit NHI Price Wire.